New restrictions and precautions for fluroquinolone antibiotics have been published, following an EU review of very rare reports of disabling and potentially long-lasting or irreversible side effects. Fluroquinolone antibiotics are no longer authorised for non-severe or self-limiting infections, or non-bacterial conditions, and for some mild to moderate infections, including acute exacerbation of chronic bronchitis, COPD, and cystitis, unless other antibiotics that are commonly recommended for these infections are considered inappropriate. Patients should be advised to stop treatment at the first signs of a serious adverse reaction, such as tendinitis or tendon rupture, and contact their doctor immediately for further advice.
Medicines with teratogenic potential
MHRA’s expert advisors have developed an aide-memoire table to provide guidance to prescribers of medicines with teratogenic potential on the frequency of pregnancy testing needed to avoid exposure in pregnancy during treatment, depending on the chosen contraceptive method. There is also new guidance on effective contraception and pregnancy testing for medicines of teratogenic potential.
Other articles cover:
- Onivyde (irinotecan, liposomal formulations): reports of serious and fatal thromboembolic events
- Letters and drug alerts sent to healthcare professionals in February 2019: Alerts highlight issues for irbesartan, amoxicillin, atropine sulfate, and paracetamol infusion.
- Medical Device Alerts issued in February 2019: Accu-Chek Insight insulin pumps, and professional use monitor/defibrillator LIFEPAK 15.